Podcasts about upar

In this episode we answer emails from Dave, Jeff and Peter.  We discuss a new risk parity ETF, ALLW, a social security claiming question and considerations, and how a listener has been misled regarding so-called dividend investing by misinterpreting a misleading source.Links:Father McKenna Center Donation Page:  Donate - Father McKenna CenterALLW Fund Main Page:   ALLW: SPDR® Bridgewater® All Weather® ETFOpen Social Security:  Open Social Security: Free, Open-Source Social Security CalculatorHartford Funds Dividend Fund Page:  The Power of Dividends: Past, Present, and FutureBen Felix Dividend Video:  The Irrelevance of DividendsBen Felix Dividend Video #2:  The Relevance of Dividend IrrelevanceBreathless Unedited AI-Bot summaryFinancial misconceptions can cost you dearly. This eye-opening episode tackles three critical investment topics that challenge conventional wisdom and may transform how you approach your portfolio.When State Street and Bridgewater Associates launched their All Weather ETF (ALLW), it promised the stability of risk parity with the pedigree of Ray Dalio himself. We dissect this new offering—examining its 175% leverage, complex asset allocation, and 0.85% expense ratio—to determine whether it delivers on its promises or falls into the same traps as similar products like RPAR and UPAR. For investors approaching retirement, understanding these nuances could be the difference between confidence and confusion in the decumulation phase.Delaying Social Security benefits remains one of retirement planning's most debated decisions. We cut through the noise of oversimplified break-even calculators to explore what truly matters: appropriate risk-free rate calculations, the value of guaranteed income streams, and perhaps most importantly, how your family's longevity history should influence your claiming strategy. For married couples, the analysis becomes even more critical as spousal benefits create powerful optimization opportunities that generic calculators often miss.The episode concludes by dispelling one of investing's most persistent myths: the magical power of dividends. When Hartford Research noted that "85% of the S&P 500's return came from reinvested dividends and compounding," many investors misinterpreted this to mean dividends themselves were responsible for these returns. We reveal how this fundamental misunderstanding leads investors astray, explain why dividend payments offer no advantage in today's zero-commission environment, and demonstrate why creating your own "dividend" through strategic selling provides superior tax control.Whether you're building wealth or planning your withdrawal strategy, these insights will help you see beyond marketing claims to make decisions based on financial reality rather than comforting illusions. Listen now to align your investment approach with actual market mechanics instead of persistent financial folklore.Have a question about risk parity investing or portfolio construction? Email frank@riskparityradio.com or visit riskparityradio.Support the show

Dive into the world of investment strategies with our latest episode focused on risk parity and the innovative ETFs, RPAR and UPAR. Join financial expert Alex Shahidi as he unpacks the evolving landscape of portfolio management, encouraging listeners to reassess their traditional views on asset allocation. The conversation covers the importance of diversification, revealing the limitations of the conventional 60/40 model that many investors continue to favor. With insights backed by historical data, we explore how equities, commodities, treasuries, and gold have performed through various market cycles. Shahidi clarifies the concept of risk parity, shedding light on how it can create a resilient investment portfolio that adapts to market fluctuations while aiming for consistent returns. He discusses the potential returns from traditionally lower-risk assets, explaining how leverage can enhance their performance to match or even exceed that of equities. Through this engaging discussion, listeners gain a better understanding of how to structure their portfolios for greater stability and consistency. Shahidi also highlights the risks associated with focusing solely on short-term market trends, urging investors to adopt a long-term perspective that prioritizes diversity in their asset allocation. As you tune in, consider your own investment approach. Are you gambling by putting all your eggs in one basket, or are you ready to embrace a diverse, strategic framework that stands the test of time? Share your thoughts about risk parity and how it has influenced your financial planning. Your journey to informed investing starts here—demand the answers you need and engage with us! Remember to subscribe and leave a review for more insightful discussions!DISCLAIMER – PLEASE READ: This is a sponsored episode for which Lead-Lag Publishing, LLC has been paid a fee. Lead-Lag Publishing, LLC does not guarantee the accuracy or completeness of the information provided in the episode or make any representation as to its quality. All statements and expressions provided in this episode are the sole opinion of Evoke Advisors and Lead-Lag Publishing, LLC expressly disclaims any responsibility for action taken in connection with the information provided in the discussion. The content in this program is for informational purposes only. You should not construe any information or other material as investment, financial, tax, or other advice. The views expressed by the participants are solely their own. A participant may have taken or recommended any investment position discussed, but may close such position or alter its recommendation at any time without notice. Nothing contained in this program constitutes a solicitation, recommendation, endorsement, or offer to buy or sell any securities or other financial instruments in any jurisdiction. Please consult your own investment or financial advisor for advice related to all investment decisions. Sign up to The Lead-Lag Report on Substack and get 30% off the annual subscription today by visiting http://theleadlag.report/leadlaglive. Foodies unite…with HowUdish!It's social media with a secret sauce: FOOD! The world's first network for food enthusiasts. HowUdish connects foodies across the world!Share kitchen tips and recipe hacks. Discover hidden gem food joints and street food. Find foodies like you, connect, chat and organize meet-ups!HowUdish makes it simple to connect through food anywhere in the world.So, how do YOU dish? Download HowUdish on the Apple App Store today:

Unlock the secrets to crafting a truly balanced investment strategy that withstands the test of time and market volatility. Join us for an insightful episode with Alex Shahidi from Evoke Advisors as we dissect risk parity investing and its potential to revolutionize traditional portfolio strategies. Discover how this approach aims to mitigate the shortcomings of the classic 60-40 asset allocation model by evenly distributing risk across various economic environments and asset classes.We challenge conventional wisdom by diving into historical market events like the dot-com bubble and the global financial crisis, examining how they exposed vulnerabilities in traditional investment strategies. With risk parity, we introduce a framework that seeks to spread growth and inflation risks more evenly, helping investors avoid the pitfalls of concentrating holdings in a single asset class. This conversation is packed with strategies to reduce volatility and provides insights into the dynamics of constructing a diversified portfolio, especially in the context of cash dominance and shifting economic landscapes.Explore the complexities of leveraging balanced portfolios with innovative tools like RPAR and UPAR, and learn how they can serve as strategic alternatives to maximize your investment potential. With real-world examples and expert insights, we delve into the nuances of economic cycles, interest rates, and inflation expectations. Gain an understanding of how these factors impact investments and why a diversified approach can offer both security and enhanced returns. Whether you're an aggressive investor or seeking a new diversification strategy, this episode offers valuable perspectives on navigating the ever-evolving financial markets.DISCLAIMER – PLEASE READ: This is a sponsored episode for which Lead-Lag Publishing, LLC has been paid a fee. Lead-Lag Publishing, LLC does not guarantee the accuracy or completeness of the information provided in the episode or make any representation as to its quality. All statements and expressions provided in this episode are the sole opinion of Evoke Advisors and Lead-Lag Publishing, LLC expressly disclaims any responsibility for action taken in connection with the information provided in the discussion. The content in this program is for informational purposes only. You should not construe any information or other material as investment, financial, tax, or other advice. The views expressed by the participants are solely their own. A participant may have taken or recommended any investment position discussed, but may close such position or alter its recommendation at any time without notice. Nothing contained in this program constitutes a solicitation, recommendation, endorsement, or offer to buy or sell any securities or other financial instruments in any jurisdiction. Please consult your own investment or financial advisor for advice related to all investment decisions.Sign up at LearnCorporate.com and take control of your career and finances. Sign up to The Lead-Lag Report on Substack and get 30% off the annual subscription today by visiting http://theleadlag.report/leadlaglive. Foodies unite…with HowUdish!It's social media with a secret sauce: FOOD! The world's first network for food enthusiasts. HowUdish connects foodies across the world!Share kitchen tips and recipe hacks. Discover hidden gem food joints and street food. Find foodies like you, connect, chat and organize meet-ups!HowUdish makes it simple to connect through food anywhere in the world.So, how do YOU dish? Download HowUdish on the Apple App Store today:

Nov 28,2024 Thursday : Morning : Sandhya Satsang - Morning Inn Sabase Upar Uthanevala Gyaan

Gehrai मैं ने दरिया से सीखी है पानी की ये पर्दा-दारी ऊपर ऊपर हँसते रहना गहराई में रो लेनाबशीर बद्र Doston, Zindagi ke har lamhe ko, humare har rishte ko gehrai mein utarkar dekhne par hi hum shayad sahi mayne mein zindagi ko jee sakte hain. Upar hi upar se toh hum sabhi jeete hain magar rishton ke gehrai mein jaakar unhe nibhane mein jo baat hai woh unhe casually nibhane mein nahi miti hai.  Toh aaiye, is khaas episode mein rishton ke gehrai mein utarkar samajhne ki koshish karte hain, zindagi ko gehrai se jeene ke baare mein ek interesting baatchit karkarte hain. Agar aapko yeh episode pasand aaya ho to aap please isey like, rate aur share kar lijiyga aur channel ko follow aur subscribe bhi kar lijiyega. Mujhe issey kaafi prerna milegi aur main aapka bahut aabhari rahunga. Dil Meri Jaan with Joy G, woh podcast show hai, woh manch hai jahan aap aur main milkar relationships yaani riston ke baarein mein, jazbaaton ke baarien mein, ehsaason ke baarein mein baatchit karengey, inhe samjhenge, kareeb se jaanenge, shero-shayari ki madad se, kavitaon, ghazalon, nazmon aur geeton ki madad se, philosophers ki madad se. Is podcast show ka maqsad hi rishton, jazbaaton aur ehsaason ko samajhna hai aur zindagi ko ek naye andaaz se dekhne ki koshish karna hai. Aapke saath milkar ek aisi community banani hai jahan hum ek naye nazariye se rishotn ko dekh sakein aur unhe ek behtareen tareekey se nibha sakein. Agar aap relationships ke baarein mein, emotions ke baarein, feelings ke baarein mein kuch bhi discuss karna chahtey hain ya kuch bhi share karna chahte hai to mujhe email zaroor kijiyega, mera email id hai ⁠dilmerijaanwithjoyg@gmail.com⁠ Aur doston agar aap zindagi, relationships, music mein dilchaspi rakhtein hain to kindly mujhse Instagram par bhi judein, mera Instagram handle hai @dilmerijaanwithjoyg. Main yahan shero-shayri, nazm, ghazal, sangeet ya poetry se zindagi ko dekhne ki, samajhne ki koshish karta hoon. Aap judhenge toh bahut accha lagega. Credits & Other information: Written and narrated by: Joy G Music: Pixabay Poems/Shers/Nazam used: Credit given to individual artists/ writers/creators Email: ⁠dilmerijaanwithjoyg@gmail.com⁠ Instagram handle: @dilmerijaanwithjoyg Disclaimer: Yeh episode meri niji raai hai, rishton aur ehsaason ke baarein mein meri niji soch hai jo maine zindagi se, apne tajurbe se aur auron ke rishton ko dekhkar, samajhkar haasil ki hai. Maine poori koshish ki hai ki aap ke samne jo bhi pesh karun woh sahi ho. Agar aapko kuch bhi galat lagey toh kindly mujhse share karein aur main immediately usko sudharne ki poori koshish karunga! Aur is episode mein maine meri likhi hui kavitaein, shero-shayari, geet, nazam aur ghazal ka allava kisi bhi dusre artist ka ya funkaar ka kuch bhi ullekh kya hai uska maine credit unko diya hai. Agar usme koi bhi truti hui ho toh main kshamaprarthi hoon!  

एक उम्र-दराज अमीर पति-पत्नी के शयनकक्ष की बातचीत व व्यवहार की झलक ।

Sarapani Te Upar Nahin Balia, ਸਰਪਨੀ ਤੇ ਊਪਰਿ ਨਹੀ ਬਲੀਆ (Sri Guru Granth Sahib Page 480 Sabad 1235)

Los amores, la vida cotidiana, la naturaleza, la amistad, la tradición y la parranda son materia prima poética del vallenato, un fenómeno musical que trasciende las fronteras de su Colombia natal. Valledupar, capital del norteño departamento del Cesar, se considera la capital mundial de este género reconocido como Patrimonio Cultural Inmaterial de la Humanidad por la Unesco. El cantautor valduparense Chabuco, nombre artístico de José Darío Martínez, nos acompaña en un paseo muy musical por los rincones y recuerdos de su ciudad. Al pasar por la céntrica plaza Alfonso López nos regala una versión en acústico de "El arcoíris", sencillo de su trabajo 'Chabuco Tango'. En nuestro periplo, que pasa por lugares como el Centro Artesanal Calle Grande, el Parque de la Leyenda Vallenata, la orilla del río Guatapurí o el mirador del Santo Ecce Homo, conocemos a varios integrantes de la Academia de Historia del Valle de Upar: su presidente, Leovedis Martínez; el compositor y escritor Tomás Darío Gutiérrez; y el también músico y profesor Simón Martínez Ubárnez. Contamos además con la secretaria de turismo de la alcaldía de Valledupar, María Martha Lacouture, y el guía Jhon Bonilla, que nos propone un interesante recorrido hacia el departamento vecino de La Guajira tras los pasos del famoso artista vallenato Diomedes Díaz, apodado El Cacique de La Junta.Escuchar audio

Bhajan

Zindagi Ke Kis Maqam Par Nigah Neechi Aur Upar Rakhni Chahiye? - by Qibla Syed Sarfraz Ahmad Shah SahabSubscribe to Syed Sarfraz Ahmad Shah Official YouTube Channel ▶️ https://www.youtube.com/@syed-sarfraz-a-shah-official/?sub_confirmation=1Excerpt from 40 Ilmi Nishistien Book - Chapter 39- Page 302Read the full chapter here

Atm gyan or akelapan kr upar ap ko rai kya hogi ? --- Send in a voice message: https://podcasters.spotify.com/pod/show/thisisspirituality/message

O que "upar a ficha" significa pra vocês? Momentos de glória? Um processo burocrático? Nada de mais? No programa de hoje, falamos sobre como diferentes sistemas abordam o desenvolvimento mecânico das personagens, e como ele pode ser mais ou menos relevante dependendo do jogo. Quem quiser anunciar com a gente, pode entrar em contato com contato@pausaparaumconteudo.com.br Usem o cupom caquitas10 na ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Retropunk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ pra ganhar 10% de desconto nos produtinhos lindos; e o cupom CAQUITAS5 na ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Forja Online⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ para 5% de desconto em toda a loja! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LISTA DE PRESENTES DO CAQUITAS⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ No mais, sigam o ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Caquitas nas redes sociais⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, e se quiserem virar nossos padrinhos, dá pra assinar pelo ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PicPay⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apoia-se⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ou pelo ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Padrim⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! --- Send in a voice message: https://podcasters.spotify.com/pod/show/caquitas-podcast/message

Shalwar Takhno Se Upar Rakhna - by Syed Sarfraz Shah

In this episode we answer emails from Drew, Carlos and Eric.  We discuss the UPAR and RPAR risk parity ETFs and their construction, rant a bit about TIPS, discuss attractive narratives about de-dollarization in the context of cognitive biases (the possibility effect and ignoring base rates) and how our adult children use a Golden Ratio-style portfolio to save for intermediate goals.Links:Father McKenna Center donation page:  Donate - Father McKenna CenterUPAR webpage:  UPAR Risk Parity ETF (rparetf.com)Michael Kitces interview:  Michael Kitces: How Higher Yields Affect Asset Allocation and Retirement Planning | The Long View (simplecast.com)De-dollarization article:  De-dollarization Has Begun. | AIERSupport the show

In this episode we answer emails from Kevin, Graham and Boone.  We discuss the risk parity ETFs, RPAR and UPAR, leveraged portfolios, alternative assets, ETFs and some of the podcasts I'm listening to these days.Links:RPAR webpage:  RPAR Risk Parity ETF (rparetf.com)Risk Parity Book Review:  Top 10 Risk Parity Resources: #10... Shahidi (2021) (riskparitychronicles.com)CFA Institute Manual Article:  chapter-4-from-managing-multiasset-strategies-2018.pdf (callan.com)Rational Reminder Video about Leverage:  Investing With Leverage (Borrowing to Invest, Leveraged ETFs) - YouTubeSound Investing Podcast:  Sound Investing on Apple PodcastsMoney With Katie Podcast:  The Money with Katie ShowMoney With Katie Portfolio Analysis Blogpost:  How to Diversify Outside of the Total Stock Market — Millennial Money with KatieRamit Sethi Podcast:  Podcast - I Will Teach You To Be RichMacro Trading Floor Podcast:  The Macro Trading Floor on Apple PodcastsEurodollar University Podcast:  General 2 — Eurodollar UniversityGestalt University Podcast:  Resolve's Gestalt University on Apple PodcastsAlpha Exchange Podcast:  Alpha Exchange on Apple PodcastsExcess Returns YouTube Channel (Corey Hoffstein Episode):  Show Us Your Portfolio: Corey Hoffstein - YouTubeRetirement Planning Education YouTube Channel:  Retirement Planning Education - YouTubeSupport the show

Jis ke sir upar

Furaman Tera Sirai Upar, ਫੁਰਮਾਨੁ ਤੇਰਾ ਸਿਰੈ ਊਪਰਿ (Sri Guru Granth Sahib Page 338 Sabad 866)

Upar a ficha, conversar sobre expectativas, discutir desenvolvimento de história e personagens... Normalmente pensamos que jogo é rolagem de dados e interpretação, e tudo o que sai disso está travando o jogo, mas será que é isso mesmo? Hoje a gente vai falar de partes do jogo que vão além de rolar e interpretar. Quem quiser anunciar com a gente, pode entrar em contato com contato@pausaparaumconteudo.com.br Usem o cupom caquitas10 na Retropunk pra ganhar 10% de desconto nos produtinhos lindos; e o cupom CAQUITAS5 na Forja Online para 5% de desconto em toda a loja! No mais, sigam o Caquitas nas redes sociais, e se quiserem virar nossos padrinhos, dá pra assinar pelo PicPay, Apoia-se ou pelo Padrim! --- Send in a voice message: https://podcasters.spotify.com/pod/show/caquitas-podcast/message

In this episode we do an annual review of the seven sample portfolios you can find at Portfolios | Risk Parity Radio.   We compare them with standard funds including VBIAX (60/40), VWENX, VWIAX, risk parity funds including RPAR and UPAR, and ultra-diversified funds including AQRIX and QDSIX.  And we conclude with some take-away thoughts from this disaster of a year as predicted by Quasimodo.Additional links:Risk Parity Chronicles Resource Page:  Resources - Risk Parity ChroniclesRPAR and UPAR Descriptions:  RPAR Risk Parity ETF (rparetf.com)AQRIX Fund Page:  AQR Multi-Asset Fund - AQRIXQDSIX Fund Page:  AQR Diversifying Strategies Fund - QDSIXSupport the show

Do kahaaniyaan. Hum dekhenge inmein...cheezein...jo dilchaspi jagati hain, aur kabhi kabhi- khauf. ________________ "Sadak ki roshni mein maine dekha ki un sab ke chehre aasuon se bheege hue they. Wo ro, cheekh, chilla rahe the..." Story 1 : "Face in the Clouds" by Max Lobdell https://unsettlingstories.com/2016/09/04/the-face-in-the-clouds/ ________________ "Ye dekh kar Mriganko babu ne socha, zarur bandaron se manushya ka parivartan mujh mein poori tarah se poorna nahi hua." Story 2: "Mrigankobabor Ghotona" by Stayajit Ray https://www.goodreads.com/book/show/475193.A_Face_in_the_Dark_and_Other_Hauntings ________________ Original Logo art by Rizky - https://www.instagram.com/step_one_studio/?hl=en Original story illustrations by: Ruchika - https://www.instagram.com/ruchika_khati/?hl=en Music production and background score by Sid Ramalingam - https://www.youtube.com/channel/UCfBYKKIokA3yzb5DGbL8m8w https://www.instagram.com/sidramling/ Mix by: Somnath - https://www.instagram.com/sagunteddy1/?hl=en Video editing by Srinath Ramalingam https://www.youtube.com/channel/UCVpOp6n09SvIe5wnnZRzGzQ https://www.instagram.com/srinath_n_r/ Voices: Nishta Jeeva Translation: Apoorv Pallavi __________________ Channel links: Spotify - https://open.spotify.com/show/2JCtbkgPg8Vs0zvUhUyYNk Apple - https://podcasts.apple.com/us/podcast/karan-ki-khaufnaak-kahaaniyaan/id1636781196 Youtube - https://www.youtube.com/channel/UC2ltvbhTCqFfd6f5xzPMRWg __________________ 00:00 - Intro 01:15 - Commentary 04:05 - Story 1 : Baadalon mein woh chehra 13:28 - Commentary 2 15:37 - Story 2 : Mriganko Babu ki Ghatana 30:17 - Further listening and Credits #podcast #horrorstories #nishtajeeva #dishtibomma #nishta #jeeva #englishhorror #horrorpodcast #horrorpodcaster #lovecraft #hplovecraft #horrorgaming #rakshasa #rakshasi #creepypasta #nosleep #johncarpenter #hindi #hindihorror #hindihorrorstory #ghoststories #hindighoststories #paranormal #creepy #supernatural #bollywood #redditstories #psychological #ritual #demon #demonslayer #exorcism #exorcist #chilling #dark #bhoot #pisacha #occult #occultist #horrorstory #synthwave #80shorror #india #indianhorror #tumbbad #stephenking #ariaster #junjiito #satoshikon #midsommar #corpsehusband #khoonimonday #aavirbhaav #telugu #hyderabad #dubstep #dubstepmusic #trapmetal #heavy #progressive #progressivemetalcore #gangsofwasseypurmemes #gangsofwasseypur #anuragkashyap #nawazuddinsiddiqui

Hamaare dvaar ke paar mitron ki kahaaniyon ke bina kya horror show ho sakta hai? Suniye, is baar 4 khaufnaak kahaaniyaan! ________________ "Mai use bilkul nahi dekh paa Rahi thi, par uski chudiyan zor se khanak rahi thi aur payal dhire dhire chan chan kar rahi thi." Story 1 : "Dancing Down an Indian Hallway in Darkness" by anonymous https://creepypasta.fandom.com/wiki/Dancing_Down_an_Indian_Hallway_in_Darkness ________________ "Chalo aa jao beta tumein itni raat ko yaha nahi hona chahiye. Mujhe batao kya pareshani hai. Upar dekho!” Story 2: "Face in the Dark" by Ruskin Bond https://www.goodreads.com/book/show/475193.A_Face_in_the_Dark_and_Other_Hauntings ________________ "Raaste mein wo ajnabi kabristaan ki taraf mud gaya, jiski vajah se doctor sahab ko ruk kar sawal karna pada." Story 3 : "It's an Emergency, Doctor!" by u/zeeshan_haroon and adapted for podcast format by Nishta Jeeva https://www.reddit.com/r/nosleep/comments/4vlkf6/a_doctor_in_a_small_town_in_india/ ________________ "Yatra ko kuch 10 minute huye honge ki maine dekha Abdul ne car ka meter nahi chalaya hai..." Story 4 : "The Cab Driver" by u/hrish02 https://www.reddit.com/r/nosleep/comments/25m4un/the_cab_driver/ ________________ Original Logo art by Rizky - https://www.instagram.com/step_one_studio/?hl=en Original story illustrations by: Ruchika - https://www.instagram.com/ruchika_khati/?hl=en Rahul - https://www.instagram.com/snuffa_luffa_gus/?hl=en Music production and background score by Sid Ramalingam - https://www.youtube.com/channel/UCfBYKKIokA3yzb5DGbL8m8w https://www.instagram.com/sidramling/ Mix by: Kalai - https://www.instagram.com/kalaidev/?igshid=YmMyMTA2M2Y%3D Somnath - https://www.instagram.com/sagunteddy1/?hl=en Video editing by Srinath Ramalingam https://www.youtube.com/channel/UCVpOp6n09SvIe5wnnZRzGzQ https://www.instagram.com/srinath_n_r/ Voices: Nishta Jeeva Translation: Apoorv Neha Pallavi __________________ Channel links: Spotify - https://open.spotify.com/show/2JCtbkgPg8Vs0zvUhUyYNk Apple - https://podcasts.apple.com/us/podcast/karan-ki-khaufnaak-kahaaniyaan/id1636781196 Youtube - https://www.youtube.com/channel/UC2ltvbhTCqFfd6f5xzPMRWg __________________ 00:00 - Intro 01:15 - Commentary 03:55 - Story 1 : Andhere Mein Naach 07:11 - Commentary 2 10:21 - Story 2 : Andhere Mein Woh Chehra 16:10 - Commentary 3 19:20 - Story 3 : "Emergency hai, Doctor!!" 28:30 - Commentary 4 30:53 - Story 4 : "The Cab Driver" 37:30 - Further listening and Credits #podcast #horrorstories #nishtajeeva #dishtibomma #nishta #jeeva #englishhorror #horrorpodcast #horrorpodcaster #lovecraft #hplovecraft #horrorgaming #rakshasa #rakshasi #creepypasta #nosleep #johncarpenter #hindi #hindihorror #hindihorrorstory #ghoststories #hindighoststories #paranormal #creepy #supernatural #bollywood #redditstories #psychological #ritual #demon #demonslayer #exorcism #exorcist #chilling #dark #bhoot #pisacha #occult #occultist #horrorstory #synthwave #80shorror #india #indianhorror #tumbbad #stephenking #ariaster #junjiito #satoshikon #midsommar #corpsehusband #khoonimonday #aavirbhaav #telugu #hyderabad #dubstep #dubstepmusic #trapmetal #heavy #progressive #progressivemetalcore

How 22 of us got into our so called secret society.... the secret was, how did we manage to enter it? --- Send in a voice message: https://anchor.fm/vaibhav-backbencher/message

ਉੱਪਰ ਦੀ ਆਮਦਨ- ਕਰਤਾਰ ਸਿੰਘ ਦੁੱਗਲ Upar Di Amdan- Kartar Singh Duggal With the passage of time the morals of our society are declining and decaying. The ethics which were supposed to cherish the past, maintain the present and shape the future have turned into a complete hoax. This greed and lust has dishonored the sense of rationality which was the best of the things that have been gifted by almighty himself. But, why this all happened? Has it anything to do with the way we look and perceive the bad and good deeds. But, why we have all have gone through this? Upar di amdan is one of the most famous work by the renowned writer Kartar Singh Duggal. The cover art of this audiobook has been made by the artist Gurdish Pannu and Dr. Ruminder has given voice to this punjabi short story. #ministory #audiolibrary #shortstory #trendingpodcast #punjabi #punjabifolk #audiobook #punjabishortstories #punjabistories #writer #listenaudiobooks #artistgurdishpannu #emotional #punjab #shorts #drruminder #punjabikahaniyan #punjabiaudiobook #audiobooks

Ghar waale kehte hain ki umar nikal gayi to shaadi hone mein dikkat hoti hai... Jigar ke ghar wale bhi aise hi hain. Jinhe chinta Jigar ki badhti umra ke sath sath Jigar ko na milne waali naukri ki bhi hai... Upar se Jigar ke sir ke girte baal !! Kya badlegi Jigar ki kismat .. Kya kabhi kha paega jigar Shadi ka Laddoo !?

Tucch Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Tucch Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Tucch Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Tucch Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Tucch Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Tucch Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Tucch Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Tucch Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Professors Scott Friedman and Neil Henderson join the Surfers (including the returning Stephen Harrison) to discuss some truly exciting advances in the basic science and technology of defining, diagnosing and treating NAFLD and NASH. This conversation focuses largely on the implications of potentially exciting future technologies such as the mRNA/CAR-T therapy described in Conversation 17.1 on NASH drug development today.After the earlier discussion of the potential future mRNA/CAR-T therapy, Scott Friedman turns to Neil Henderson and asks this question: "What cell type and what receptors on those cells do you hone in on or do you do more than one? And how do you use single cell genomics to help you sort through that complex question?"Neil immediately connects the question and the technology to the need for precision medicine in NASH. He points out that one challenge with NASH is hitting a single target is always challenging, particularly when the target is as "evolutionarily conserved" as fibrosis. To Neil, this suggests that if the mRNA/CAR-T therapy comes to fruition, it will become one element -- an important one, but not the only one -- in what he describes as "multimodal combinatorial therapy" which combines medicines and technology to attack fibrosis, perhaps all at once or possibly in stages.Stephen Harrison says this information leaves him feeling like he is "very much at the very tip of the archeological dig" into what we know about treating Fatty Liver disease. He points out that one rule in drug development today is "if you get rid of the fat, the liver will take care of itself." Following this logic, he suggests the best place for something like the mRNA/CAR-T approach might be in cirrhotic or pre-cirrhotic patients with the goal of regressing fibrosis sufficiently that other more metabolic drugs might become appropriate and adequate as therapyScott points out that 90% of all fatty livers never go on to develop cirrhosis. Given this fact, one key focus of learning must be determine why it is that some livers progress and others do not. This would allow us to develop therapies targeted at the livers that progress and the cellular or genetic factors that lead them to do so. This, Scott points out, leads us back to the question of how we can use single cell technologies to learn the role that each cell type plays at different points in disease progression. This leads to a discussion between Neil, Scott and Stephen about the specific challenges of obtaining the liver tissue necessary for these kinds of assessments.

Professors Scott Friedman and Neil Henderson join the Surfers (including the returning Stephen Harrison) to discuss some truly exciting advances in advanced NASH omics, including work on mRNA/CAR-T anti-fibrotic therapies. There is not enough room to capture this entire conversation in a summary. It's a lot, but really eye-opening and exciting. Take the time to listen to the entire episode, even if in bite-sized pieces.This episode starts with bonhomie and humor as the group congratulates Professor Friedman on being honored with a Lifetime Achievement Award from the faculty at Mt. Sinai, and then listens as Professor Henderson relates one of the most truly unique "one thing you wouldn't know about me if I didn't tell you" in the history of the podcast.The science portion of the podcast starts with Scott discussing a fantastic series of advances in basic science, wherein researchers have begun to evaluate CAR-T therapy, which was originally developed to treat lymphomas and other blood dyscrasias, to attack the surfaces of fibrogenic cells in the liver (MSK, New York) or, separately, the heart (University of Penn). Today, we create CAR-T cells by taking cells from the diseased patient, re-engineering them and injecting them back into the patient. This approach  is associated with high rates of Level 3+ cytokine response syndrome (CRS). It has also been found to leave this engineered CAR-T material in the patient's system for at least a decade after therapy.Scott goes on to explain how the Epstein lab at Penn integrated the CAR-T strategy with mRNA, the protein behind the Pfizer/BioNTech and Moderna DOVD-19 vaccines, to create a vaccine that can reprogram cells within the body to replicate the CAR-T effect. Scott notes that so far, this has only been reported in mouse models, and that there are many major issues to resolve before we know it will be safe and effective in humans. It is a staggering  breakthrough nonetheless.After a couple of questions, the group turns to Neil, who points out that this kind of finding can help "make precision medicine a reality," in part because it creates the possibility we can target multimodal therapy at the precise location it is needed. Stephen suggests that the ideal place for this kind of therapy might be in a late-stage patient where we can regress fibrosis and, once the liver is better able to function, resort to a more metabolic therapy. Scott suggests how helpful it would be to develop insight into how different types of cells respond to different medication, which shifts the conversation  toward the broader topic of single-cell genomics, and specifically, the growing utility of spatial transcriptomics in these situations. Neil provides a description of the benefits of spatial transcriptomics, and then takes the group back  through a history of omic technology.Jörn Schattenberg asks what these techniques have taught us about variability between patients. Neil discusses the congruence of individual samples.  Jörn points out this would mean that we can develop robust therapies targeted at a cell type. Scott suggests that we can use these insights to standardize clinical trials, to target the specific patients with the genetic targets most likely to respond  -- a large step on the path to personalized precision therapy.In response to a question from Louise Campbell about sources for liver tissue, Neil asks for study purposes, "What is a normal human liver?" One of his major sources of tissue  are distal liver sites from patients with colorectal cancer. However, even if these are cancer free, thy could be affected by chemotherapy.As discussion winds down, the group comes to focus on the issue of why and how the liver regenerates. It raises fascinating questions: why does it not seem to "over-regenerate?" Are the regenerated cells different from pre-injury cells, and if so, how?

Gariba Upar J Khinjai Dhari, ਗਰੀਬਾ ਉਪਰਿ ਜਿ ਖਿੰਜੈ ਦਾੜੀ (Sri Guru Granth Sahib Page 199 Sabad 507)

In this episode we address emails from Rory (x2), Frank, Andy and Mark.  We discuss UPRO issues, where to put gold, role models for retirement, Andy's experiments with UPAR and Mark's wonderful new tool and options strategies for reducing stock market risk.Links:Kitces Analysis of Morningstar Safe Withdrawal Rate Report:  Can Morningstar's Withdrawal Rate Report Refute The 4% Rule? (kitces.com)Andy's UPAR Bogleheads Forum Link:  The Tobin Two-Fund Portfolio - Bogleheads.orgMark's Most Excellent Portfolio Shortcutter Tool:  https://docs.google.com/spreadsheets/d/1lG18XrJA8-oODSNC0nV2T5nyVPAByU7p901oYn_ECDw/edit#gid=1553040997A famous stand-up philosopher:  A Standup Philosopher - YouTubeSupport the show (https://www.riskparityradio.com/support)

Gur Ke Charan Upar Mere Mathe, ਗੁਰ ਕੇ ਚਰਣ ਊਪਰਿ ਮੇਰੇ ਮਾਥੇ (Sri Guru Granth Sahib Page 187 Sabad 447)

Un episodio que suena al compás del acordeón. Llega a nuestra narración el Festival de la Leyenda Vallenata. El epicentro es el Valle de Upar, pero recoge las raíces de lo que sería el Magdalena Grande «Magdalena, César y La Guajira». A orillas del río Guatapurí, recordaremos la historia de Francisco el Hombre, la relación que tenía nuestro nobel Gabriel García Márquez con el Vallenato y como no el empeño que tuvieron Rafael Escalona y Consuelo Araujo para sacar adelante un Festival que enaltece la vida del juglar y le da el gran significado a ser Rey vallenato. Notas del episodio: El Vallenato del Magdalena Grande La Sierra Nevada y la línea negra Los griots: narraciones desde el África Occidental La historia de Francisco el Hombre  El nobel colombiano y su inspiración en el Vallenato Los viajes del Viento «película» La magia del Acordeón  Las mujeres del Vallenato «festival Evafe» Agradecimientos: Consuelo Sanchez Sandra de Evafe Frank Solano Alberto Salcedo Ramos Ivan Medellin @civanmedellin Grupo de Patrimonio Cultural Inmaterial del Ministerio de Cultura ¡Síguenos en nuestras Redes Sociales! Pagina web: https://www.dianauribe.fm Facebook: https://www.facebook.com/DianaUribe.fm/ Instagram: https://www.instagram.com/dianauribef... Twitter: https://twitter.com/dianauribefm?lang=es

A story that depicts the value of love in life and how if there is  affection within a family, the rest will fall in place

LYRICS=Akela raat ke chaar baje, Zahen me saawal bhare, Ghum raha darbadar, dilo me haazar wahem bhare, Haath khali raat kaali, Upar se ye sarr bhari, Aur thora sa ye yaad bhare, Kal ki yah baat khare, Baat jo the kai saare, Ek ek karke jo aarahe, Kaale andhere, Dheere dheere yu sata rahe, Khafa jo ateet se Zahen mere, Na jane kitne ye raat jage, Ab darr lagta roshini sar sawere, Yu yeh raat bhare, Ab naa taare jagte, Na neende aate, Khwab kafi saare, Ek ek kar sata rahe, Na jata paa rahe, Aur wo jaa rahe, Akele aj raat ke chaar baje, Alfaz mere dard bhare, Arzj kar rahe, Na soch tu re, Dard hai marz, Marzi ya aarzi tere, Zaher jab chaar baje, Ab baithe na soch re, Mann me sawal bhare, Aur kaise yeh Izhaar kare, Ya samajhdaar bann sawera ka intizaar kare...

Dr. Anthony Rullo, PhD, Assistant Professor of Medicine at McMaster University discusses the Anna Biosciences Syntem Platform that deploys engineered proprietary molecules to create synthetic immunity. Research suggests the platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. In partnership with McMaster University, Anna Biosciences has proven its initial successes in the laboratory and is now accelerating its commercialization effort to bring this potential COVID-19 treatment to market. The platform also shows strong promise for use against cancer and other pathogens. #AnnaBiosciences #Syntem #COVID19 Anthony Rullo, Ph.D, is an Assistant Professor of Medicine at McMaster University where he has pioneered small molecule “proximity-inducing” therapeutic strategies with applications in immuno-oncology and anti-viral immunotherapeutics. In 2017 he founded the Rullo Laboratory, a translational chemical biology lab integrated within the department of medicine and the McMaster Immunology Research Center (MIRC). Dr. Rullo's scientific training encompasses several aspects of organic synthesis, carbohydrate chemistry, physical biochemistry, and immunology. He received his Ph.D. in Organic and Biochemistry from the University of Toronto under the supervision of Prof. Mark Nitz, where he developed fluorescent chemical probes of complex glycosaminoglycan binding interactions, in addition to new bio-orthogonal affinity labelling strategies. This was followed by postdoctoral training under the mentorship of Prof. David A. Spiegel at Yale where Dr Rullo pioneered the development of synthetic antibody engagement molecules targeting uPAR expressing cancers. With his leading role in the development of the Syntem Platform, Dr. Rullo serves as the scientific co-founder of Anna Biosciences. As part of the development of the Syntem Platform, Dr. Rullo has engaged supporting experts in medicinal chemistry and immunology/virology.

Quran Pak Mein Pechli Qoumon k Upar Any Waly Azab k Bary Mein Kya Kaha Gaya Hai? | 07 July 2021 | Subh E Noor

Listen to short summaries of the latest oncology-focused research published in this week's issue of Oncotarget, Volume 12, Issue 14. https://www.oncotarget.com/archive/v12/i14/ Cover Paper - “Esomeprazole enhances the effect of ionizing radiation to improve tumor control” https://doi.org/10.18632/oncotarget.28008 Research Paper - “Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer” https://doi.org/10.18632/oncotarget.28014 Research Paper - “MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer” https://doi.org/10.18632/oncotarget.28002 Research Paper - “The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma” https://doi.org/10.18632/oncotarget.28013 Research Paper - “Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia” https://doi.org/10.18632/oncotarget.28000 Research Paper - “Prokineticin-1 induces normal lymphangiogenic activity and is involved in lymphangiogenesis and lymph node metastasis in colorectal cancer” https://doi.org/10.18632/oncotarget.28016 Research Paper - “Appropriate body mass index cutoffs for type 2 diabetes in Xinjiang population: defining the influence of liver aminotransferase” https://doi.org/10.18632/oncotarget.28009 Review - “Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment” https://doi.org/10.18632/oncotarget.28010 Research Perspective - “Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives” https://doi.org/10.18632/oncotarget.27936 Research Perspective - “A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies” https://doi.org/10.18632/oncotarget.27960 Keywords - mebendazole, pancreatic cancer, esomeprazole, tumor control, MRI, breast cancer, eltrombopag, colorectal cancer, AML, type 2 diabetes, chlorpromazine, immunotherapy, tumors, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Bom Dia

Voice by Monashree ❤

El vallenato es un género musical tradicional, que tiene origen en el norte de Colombia, es decir en el Valle de Upar, lo que hoy se conoce como Valledupar. Una mezcla de sonidos que busca promover y fortalecer el diálogo entre generaciones, a través de relatos de la vida cotidiana y la realidad. Por esta razón, en nuestra emisión de hoy hablaremos sobre 10 artistas afros del género, que demuestran que en la actualidad es un patrimonio que no se queda solo en el Caribe, sino que recorre varias partes del país. Conduce: Evelin Asprilla

Deh Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Deh Se Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Username - @dilhaicricket. Is instagram account/facebook page par mujhe DM karke bataiye ki aap konse topic par podcast episode chahte hai. Mai jitni Jaldi ho sake, us topic par ek podcast episode, apke is channel - Dil Hai Cricket, par launga. --- Send in a voice message: https://anchor.fm/subrata-biswas01/message

El poder de la historia en la comunicación La historia. La narrativa. El Story telling. ¿A quién no le gusta una buena historia? El escritor y cineasta Andrés Lopera comparte sus conceptos sobre la historia en esta entrevista. La era de Oro del Podcast (razones para amar este lenguaje) Nuestro invitado para hablar del poder de las historias y la comunicación es Andrés Lopera Sánchez. Andrés es escritor, creador y productor, pionero en nuevos medios y formatos. Es administrador de negocios y de Eafit. Sin embargo, en algún momento su vida dio un giro importante y se dedicó a contar historias. Los proyectos en los que ha participado han ganado múltiples premios nacionales e internacionales, dentro de los que se destacan los Premio TAL 2017 por mejor serie educativa de Latinoamérica, científico por un día, cuatro premios EFI, los corredor. Escribió los largometrajes Guayabo, Yo sí maté al Protero y aquellos amores imperfectos, algunos de ellos en posproducción, otros en preproducción. También escribió los documentales Vallenato, Valle de Upar para el mundo, Un Dial de historias y territorio natural. Entre sus creaciones para nuevos medios se destacan las series webs Adulto Contemporáneo y Los Corredor y el podcast Gajes del Oficio. Fue Gerente de RCN Cine y es socio fundador CEO director creativo de la buena estrella desde 2014. Además, fue el fundador en 1990 del cine club Eafit. Así que sin más preámbulos el poder de la historia y la comunicación con nuestro invitado Andrés Lopera Sánchez. Recuerda por favor escucharnos y suscribirte en la plataforma que más te guste: Apple Podcast - http://bit.ly/appleMP Spotify- http://bit.ly/spotifyMP Google Podcast - http://bit.ly/googleMP Para participar, escríbeme tus comentarios a santiagorios(ARROBA).com.co Recursos recomendados en este Podcast Podcast ¿Quién es el héroe de tu comunicación? https://www.milpalabras.com/2020/10/07/74-quien-es-el-heroe-de-tu-comunicacion/ Viviendo de la narrativa https://www.facebook.com/groups/viviendodelanarrativa Andrés LoperaSánchez en Linkedin https://www.linkedin.com/in/andres-loperas%C3%A1nchez-13769816/ Andrés LoperaSánchez en IMDB https://www.imdb.com/name/nm11972230/ http://labuenaestrella.co/ Suscríbete al Podcast de Mil Palabras en www.milpalabras.com Descarga GRATIS el ebook “Cómo Crear un Podcast Corporativo” https://milpalabras.com.co/guiapodcast/ Quizás quieras escuchar el episodio anterior #104 Elementos de un sitio web ganador https://episodes.castos.com/5eec139be49343-25958662/-104-Que-debe-tener-un-sitio-web-vendedor.mp3

Mein Ke Upar Aham Ka Parda Hai : Pujya Sant Shri Asharamji Bapu Satsang

Mein Ke Upar Aham Ka Parda Hai : Pujya Sant Shri Asharamji Bapu Satsang

On this episode, Pallavi talks to Neelam Kumar, a two time breast cancer 'beater' as she calls herself, who believes 'Obstacles are opportunities in disguise.'  Can Inspire is Production of WYN Studio. Hosted by C Pallavi Rao Narvekar. Produced by Prapti Khanna, Executive Production by Bijay Gautam and Souniya Khurana. Editing and Mixing by Shrey Oberoi. The show intro was created by C Ravishankar Rao. Find us at www.wyn.studio. See omnystudio.com/listener for privacy information.

This week’s episode features author Emma Birks and Associate Editor Hesham Sadek as they discuss the article " Prospective Multicentre Study of Myocardial Recovery Using Left Ventricular Assist Devices (REmission from Stage D Heart Failure: RESTAGE-HF): Medium Term and Primary Endpoint Results." TRANSCRIPT BELOW: Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast, summary and backstage pass to the journal and its editors. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, associate editor, director of the Pauley Heart Center of VCU Health in Richmond, Virginia. Carolyn, our feature article this week, we're going to examine myocardial recovery using left ventricular assist devices, getting some early results from the RESTAGE-HF study. But before we jump to the feature discussion, how about we discuss some of the papers in the issue? Would you like to go first? Dr. Carolyn Lam: Yes I would. Have you thought about what's the benefit of emergent coronary angiography after resuscitation from out of hospital cardiac arrest for patients without ST elevation? It's an important question. Well, the portal study was reported by Dr. Kern from University of Arizona and colleagues, and this was designed to evaluate the efficacy and safety of early coronary angiography and to determine the prevalence of acute coronary occlusion in resuscitated out of hospital cardiac arrest in patients without ST elevation. So adult comatose survivors without ST elevation after resuscitation, were prospectively randomized to early coronary angiography versus no early coronary angiography, where early was defined as less than 120 minutes from arrival at the PCI capable facility. The primary endpoint was a composite of efficacy and safety measures, including efficacy parameters of survival to discharge favorable neurological status at discharge echo measures of left ventricular ejection fraction, more than 50% and a normal regional wall motion score within 24 hours of admission. Dr. Greg Hundley: So, lots of data here. What did they find? Dr. Carolyn Lam: So, unfortunately the study was prematurely terminated before enrolling the target numbers of patients. A total of 99 patients were enrolled from 2015 to 2018 and 49 were randomized to early coronary angiography. The primary endpoint of efficacy and safety was not different between the two groups. Early coronary angiography was not associated with any significant increase in survival or adverse events. And early coronary angiography revealed a culprit vessel in 47% with a total of 14% of patients undergoing early coronary angiography, having an acutely occluded culprit coronary artery. So while this was an underpowered study, when considered together with previous clinical trials, it does not support early coronary angiography, comatose survivors of cardiac arrest without ST elevation, whether early detection of occluded potential culprit arteries leads to interventions that improve outcomes does require additional study. And this is discussed in an editorial by Dr. Lemkes from Amsterdam university medical center. Dr. Greg Hundley: Very nice Carolyn. So at least the study that points us toward the next study that has to be performed and also does with other studies provide a little more clarity. Well, my next paper is from Professor Sanjiv Shah and--oh, wait a minute! And also from you as a co-author. Well, Carolyn, how about we have a little mini feature discussion where I can ask you some questions and then you can tell us all about your paper. Dr. Carolyn Lam: Happy to. Dr. Greg Hundley: Great. So Carolyn, what hypotheses were you testing and what was your study design and who was included in your study population? Dr. Carolyn Lam: Okay. So the question was we wanted to answer was thus a systemic pro-inflammatory state as indicated by proteomic profiling. Does that mediate the association between comorbidities and normal cardiac structure and function in HFpEF. To answer that we studied 228 patients with HFpEF from our multicenter promis HFpEF study. And these patients had 248 unique circulating proteins quantified using the old link multiplex immunoassay. Now I'm going to describe a complex analysis, but we basically had to first perform principal component analysis. And we did this to summarize 47 proteins known a priori to be involved in inflammation, and then used unbiased network analysis of all the 248 proteins to identify clusters of proteins that over-represented inflammatory pathways. We then used a mediation analysis to determine whether and to what extent inflammation mediates the association of comorbidity burdens with abnormal cardiac structure and function. And finally, we externally validated our findings in an independent cohort of 117 HFpEF cases and 30 comorbidity controls without HFpEF. Dr. Greg Hundley: Wow Carolyn, such a great design and an app machine learning mediation analyses, and then validation in an independent cohort. So tell us, what did you find? Dr. Carolyn Lam: So first, comorbidity burden was associated with abnormal cardiac function and structure and with these principle components of clusters of inflammation proteins. Second, systemic inflammation was associated with echo indicators of worse hemodynamics, like higher EDE' ratio and worse, right ventricular function. And third, inflammation indeed mediated the association between comorbidity burden and many of these echo parameters with, and I'm going to name a couple of routines. So TNF-R1, uPAR, IGFBP-7 and GDF-15 being the top individual mediating proteins. In the validation cohort inflammation was up-regulated in HFpEF compared to controls and the most prominent inflammation protein cluster identified was also the same one as in PROMIS-HFpEF. Dr. Greg Hundley: Beautiful Carolyn. So with these new proteins identified, what's the take home message here? Dr. Carolyn Lam: Here it is. Proteins involved in inflammation form a conserved network in HFpEF. And this was found across two independent cohorts. This may mediate the association between comorbidity burden and echo indicators of worst hemodynamics and right ventricular dysfunction. In totality, these findings support the comorbidity inflammation paradigm in HFpEF. Dr. Greg Hundley: Great job Carolyn, I liked the mini feature. That was so nice having one of the authors of the study here to explain kind of a two for one here, because we're going to get a feature and a mini feature. Have you got another paper you want to tell us about? Dr. Carolyn Lam: Thanks Greg and that works both ways. This next paper provides insights into the identity origin and function of many cells that make up late stage atherosclerotic lesions. It also identifies the mechanisms by which these control plucks stability. So corresponding author, Dr. Owens from Virginia School of Medicine and colleagues conducted a comprehensive single cell RNA sequencing of advanced human carotid endarterectomy samples, and compared these with murine micro dissected advanced atherosclerotic lesions with smooth muscle cell and endothelial lineage tracing to survey all plaque cell types and to rigorously determine their origins. Dr. Greg Hundley: Carolyn you know, this is another great study where we have both human subjects research and small animals. What were their results? Dr. Carolyn Lam: They provided evidence that smooth muscle cell specific knockout of transcription factors, KLF4 versus Oct-4 showed virtually opposite genomic signatures and their putative target genes played an important role, regulating smooth muscle cells phenotypic changes. They also provided evidence that smooth muscle cell derived cells within advanced mouse and human atherosclerotic lesions exhibited far greater phenotypic plasticity than generally believed, with KLF4 regulating the transition to multiple phenotypes, including LGALS 3 plus osteogenic cells likely to be detrimental for late stage atherosclerosis plaque pathogenesis. So in summary, smooth cell phenotypic switching produces cells that can be beneficial or detrimental to lesion stability and may be an important mechanism controlling the risk of unstable atherosclerotic plaque and myocardial infarction or stroke. Dr. Greg Hundley: Oh, great job, Carolyn. Well, the next paper I have is from Professor Muredach Reilly from Columbia University. And Carolyn smooth muscle cells play significant roles in atherosclerosis via phenotypic switching, a pathological process and with smooth muscle cell D differentiation, migration and trans differentiation into other cell types yet how smooth muscle cells contribute completely to the pathophysiology of atherosclerosis remain somewhat illicit. So the authors sought to reveal the trajectories of smooth muscle cell trans differentiation during atherosclerosis, and to identify molecular targets for disease therapy by combining smooth muscle cell fate mapping and single cell RNA sequencing of both mouse and human atherosclerotic plaques. Dr. Carolyn Lam: Echoing what you said earlier, Greg, both animal and human data. Terrific. So what were the results? Dr. Greg Hundley: The authors found that smooth muscle cells transitioned to an intermediate cell state during atherosclerosis, which was also found in human atherosclerotic plaques of carotid and coronary arteries. Smooth muscle cell derived intermediate cells termed stem cells were multiphoton and could differentiate into macrophage like and fibro chondrocyte like cells as well as returned towards the smooth muscle cell phenotype. Retinoic acid signaling was identified as a regulator of the transition of smooth muscle cells to stem cells and RA signaling was dysregulated in symptomatic human atherosclerosis. Finally Carolyn, human genomics revealed enrichment of genome-wide association study signals for coronary artery disease in RA signaling target gene low PSI and correlated between coronary artery disease risk levels and repressed expression of these genes. Now, activation of RA signaling by all trans retinoic acid and the anticancer drug for acute promyelocytic leukemia blocked the smooth muscle cell transition to stem cells, and that also reduced atherosclerotic burden and then promoted fibrous cap stability. So a lot of clarification of the role of smooth muscle cells, trans differentiation and the development of atherosclerotic disease Dr. Carolyn Lam: Indeed and translational implications. Interesting. Now let's review some of the other papers in this issue. Shall we? First as an, on my mind paper by Dr. Kullo on familial hypercholesterolemia, a reportable disorder. There's an exchange of letters between doctors Lazzerini and Li regarding the article autoantibody signature in cardiac arrest. Dr. Greg Hundley: Thanks Carolyn. Well, I've got a couple other papers to tell you about really a series of research letters from the mailbag. So first Daniel Modin has a Research Letter entitled “Acute COVID-19 and the Incidents of Ischemic Stroke and Acute Myocardial Infarction.” Dr. Christian Mueller has a Research Letter entitled “Effect of a Proposed Modification of the Type 1 and Type 2 Myocardial Infarction Definitions on Incidents and Prognosis.” And finally Carolyn a Research letter from Dr. Jizheng Wang involving an East Asian-specific common variant in TNNI3 that appears to predispose to hypertrophic cardiomyopathy. Well, Carolyn, what a great issue and thank you for that many feature, but how about we proceed on next to our feature discussion? Dr. Carolyn Lam: Let's go, Greg. Today's feature paper is one of those that I think is going to change clinical practice. So please listen up. It's about the RESTAGE-HF study. So pleased to have with us the first and corresponding author, Dr. Emma Birks from University of Kentucky Gill Heart and Vascular Institute, as well as our associate editor, Dr. Hesham Sadek from UT Southwestern to discuss this very important paper. Emma, could you please describe the RESTAGE heart failure study? Dr. Emma Birks: Let's say prospective study of patients getting left ventricular assist devices. So patients with very advanced heart failure are receiving left ventricular assist devices as either a bridge to transplant or as destination therapy. And they're seeing them for chronic heart failure because really all other medical therapy has failed and we use the pump to try and recover their own heart. So when the pump's implanted, we optimize the LVAD unloading, the maximum loading, and we give them a very aggressive medical therapy regime, unless they may not have tolerated these medications before because of poor blood pressure and renal dysfunction, we find they do tolerate them. So we give them in very aggressive doses and then we monitor their underlying function at regular intervals and try and promote recovery. So with that, we had done this in England in the past, in a single center study, but it had not yet been reproduced, which was obviously essential to have a bigger impact. Dr. Emma Birks: So we did a prospective study of six big US centers. We found that we've created a primary endpoint that was statistically powered in advance. And the primary endpoint was the number of patients that recovered within an 18 month period, that were explanted and remained off the pump and alive without transplant over for one year. So overall we found that of the 40 patients we recruited in the centers with chronic heart failure, we were able to explore 19. Of those that satisfied the primary endpoint, that was actually 40% of patients, with 52.3% being explanted overall. And importantly, patients were explanted in all six centers, so we found that the protocol was reproducible under the how much higher rate of recovery that you would otherwise see. Normally there is a database in the US that tracks outcomes from bad patients. And generally only 1-2% seemed to recover enough to be explanted generally. So this was a much bigger percentage. Dr. Carolyn Lam: Emma, first of all, congratulations, what an important trial and what stunning results. More than half of patients receiving that protocol were explanted. That's just remarkable. Now, could I just ask, what is it that you did that was different? I noticed you spent a lot of time saying this was an aggressive pharmacological protocol that was along with the LVAD unloading. Could you maybe elaborate on that a little bit more? Dr. Emma Birks: Yeah, I think that was a very important part of it. So generally I think when the LVAD goes in most centers, the patients are very sick, so most of those patients wouldn't then try and recover them or look at underlying functions. I think that was the first thing that was different was to try very hard. And then we had centers, the experience, I had done this before, it was also very helpful, all agreeing to do the same thing. We use a very aggressive regime of ACE inhibitors, Beta blockers, auto serotonin antagonists and ARBs. And that was also an unusual thing. We use the fact that they're supported with the pump to use both an ACE and an ARB together, but the idea that they have better blood flow in the cranial is way more tolerant and we give very high doses. So we use Lisinopril with the target dose of 40 milligrams, Coreg with a target dose of 50 BID, Aldactone 25 milligrams daily. Dr. Emma Birks: And then we add in losartan if they tolerate it and actually aim for 150 milligrams daily, so those doses are very high. And I think not normally given to people on LVADs. So you must've had the LVAD that don't tolerate the medical therapy and stop it. They might just have blood pressure control, etc. There is now also another INTERMACS trial, a sort of big study that's come out that actually shows benefit of neurohormonal antagonists in general. So that goes together with our study to show that they should already be given and then the regular testing. So we had quite thorough testing. So first of all, we do echos on the pump and then we do echos with the LVAD turned down to a speed at which is not contributing. So we do that and we do an echo at five minutes with it down 15 minutes, and then we walk the patient, distress them. Once we show that the hearts come down in size and improved function, then we do an exercise test, right heart cath on an off pump to look at the hemodynamics. Dr. Carolyn Lam: Wow. So tremendous effort and really the protocol is unique in and of itself, not just the pharmacological therapy, also the way this is monitored and decisions are made really, really amazing. Just one last question for me, because it's a humbling reminder of the importance of neurohormonal blockade in these patients. Do you continue that after they're explanted? Dr. Emma Birks: Yes, we do. And we continue aggressively and that's slightly different as well in that normally you wouldn't give a patient a nascent an up of course, but given that they've already tolerated it on the pump in that same patient. So we restart the same drug regime afterwards, and we actually like to get them to quite along that dosage before we discharge them from the XPLAN, we don't want to do that slowly. We get them back on it quite quickly. And then we follow them very carefully because we don't really know the long-term durability. Dr. Carolyn Lam: Wow, thank you. Hesham. I would love your thoughts on this paper. I mean, it really, really is remarkable results. Dr. Hesham Sadek: Yeah. I mean, I was very happy that we received this paper to review, frankly I've been following that work for a long time since the first new England paper that came out and I'd like to congratulate you for an amazing work. I think this will change the field. First, how was this trial different from the first trial, other than the fact that it's multicenter, what would you say are the major changes that you made to the protocol and what you've learned since the first trial? Dr. Emma Birks: Yes, you're absolutely right. We did make some changes. So first of all, it was six sites instead of one site. I think it was very important to reproduce it in the US but we changed the protocol itself as well. The first trial had optimization of the LVAD speed, really just by echo looking at the reduction in the ventricle size. It had the aggressive medical regime was very similar except this time we increased the Losartan dose from 100 to 150 after the Hill's trial came out. The testing was very frequent in the original English Sheffield study, probably a little bit too frequent to be able to be adopted on a wide scale. So we tried to reduce it down a little bit. So we decrease the frequency of the low-speed echos. I think we had them at six weeks, four months, six months, nine months in a year. Dr. Emma Birks: And after that, we saw if they were already improving and started and only did them at a year to 18 months, if they were improving. And then we also cut down the number of exercise tests. So we didn't do the exercise test until the echo was already showing significant improvement. For two reasons, one, we didn't find it very reliable and two, it was just too much testing for the patient. So it was more of a confirmatory test. In fact, it wasn't a requisite for a pump explantation. We didn't do a left heart catheter, which we did before. Previously we tried to measure LVEDP, this time we decided which was enough. So we just did a right heart cath on and off pump. And we did that once the echo was improved as well. So we rationalized that a little bit. And then the other important thing was before in hayfield study, once we saw the ventricular size come down and injection fraction start to improve, we actually added in Clenbuterol, which was a Beta-2 agonist. Dr. Emma Birks: And the idea with that was to cause a kind of physiological hypertrophy so that when you took the pump out, the heart didn't just dilate. We were worried about atrophy at the heart on the pump long-term. So we did that to try and improve the durability of recovery. So the reason we left off this time was really the previous protocol was very good, but was very complicated. So we wanted to see what rate of recovery we could get just with the aggressive reverse remodeling, neurohormonal drugs, plus the aggressive testing and the optimum loading with the idea that later on, we could add on either Clenbuterol or something later to improve the durability of recovery, if the ability of recovery is not good enough, but actually so far it's proven to be pretty good because the study itself takes quite a long time. It was sort of to recruit them. We had an 18 month period than the follow-ups. It was already a multi-year study. So we wanted to establish a regime that many centers could use to try and promote recovery. Dr. Hesham Sadek: I want to follow up on that last point, because as you know, I've looked at some of these Heights as well in our center, and we looked at the results with you and Stavros and others. So the myocytes size is expected to change, decrease with unloading, right with sufficient unloading. So how would you prepare the Myocardium to take on the normal afterload if you are not going to induce by a beta agonist, for example, Dr. Emma Birks: What I would like to do in the future is try using the pump itself actually. Sometimes there's heart recovers, the heart shrinks and actually start opening their own valve and working in the heart. Of course, when you have the HeartMate one, actually, sometimes wasn't synchronous with the heart. So sometimes the heart will beat against the pump anyway. Once you go to the continuous flow pumps, you've got continuous unloading. So I think it'd be very interesting to intermittently turn down the pump speed and load the heart to work it before you take the pump out. So I would really like to do that. I think that might be the next interesting phase of the study to improve your ability to.. So I guess once you've got maximum reverse remodeling and improvement in function, you could just turn the pump speed down to let the valve open. Dr. Hesham Sadek: Do you think perhaps if you do that, you will increase the percentage of patients that can be explanted? Do you think that could be a factor in the percentage of patient that can be explained? Dr. Emma Birks: I think it might be, it might more improve the, to your ability to make sure we have for a long, good echo function afterwards. Dr. Hesham Sadek: That's great. So another question this was limited to not ischemic cardiomyopathy patients. Can you elaborate a bit on why not include, for example, revascularized ischemic cardiomyopathy patients. Dr. Emma Birks: Yeah, so we did that really just because we didn't want to change too much from the original protocol. We also stuck with one device because we thought if you have multiple pumps, multiple diagnosis, it does get hard to analyze in a multicenter trial. So we did that on purpose and we were always trying to simulate the bridge to transplant population in the age group too. But actually interestingly, most of the patients recruited in the trial were destination therapy patients in the end. Dr. Emma Birks: I think this could be done with ischemic cardiomyopathy. I think we don't have enough data on ischemic cardiomyopathy to know whether it does or it doesn't recover. So I don't think our results say that it's only known as ischemics. I think it just means we haven't studied ischemics sufficiently. Logically they might have more scarred. It might be harder to get such a good percentage to recover. I think all of us in our individual centers have seen a few and we've sort of seen the on pump echo improved, and we've tested them and then taken some out. But most of these cases are anecdotal. So I think that is another important study that needs to be done, obviously a large group of patients. Dr. Hesham Sadek: I agree. So given that they're not ischemic cardiomyopathy, do you know how many of them had genetic testing or what is the percentage of monogenic cardiomyopathys or how do you think these patients would respond to this protocol? Dr. Emma Birks: But if you had a familiar history and actually found it didn't make any difference, whether they recovered or not. I think some of us have personally seen actually those were the familial cardiomyopathy tend to recover more actually again, anecdotally. We published a people before looking at the Titin gene saying that that did recover. I think actually only five of these patients, 12% of them had a family history, but some of them recovered Dr. Hesham Sadek: One final question, as you know, I'm a basic scientist. So ultimately the question I'm going to ask, what do you think the mechanism is? Is it that these hearts are just in a vicious cycle of remodeling and validation, increased pressure, and you were sort of giving it a chance for actual structural reverse remodeling where you changed the geometry of the myocardium and perhaps rest of myocardium, allow for improvement of calcium cycling dynamics, or do you think, is something more exciting? Like three-generation for example. Dr. Emma Birks: Yeah, that's very interesting because I think the LVAD doesn't unload, so it shrinks the ventricles. I think it does improve the geometry and the dynamics. And then you use the drugs where they may have felt before you almost put them from class four, heart failure into class three with the bad to give that chance to work again. And then I think various cellular and fibrotic factors have been looked at and it's hard because there was so many factors have been looked at that. You were going to find some that go up and some that go down and what's important. But the impression I get overall is that you do get improvement, the matrix limits, the recovery on the fibrosis and the matrix. Whereas you do get improvements of myocardial function and cellular function. The cells will tend to reverse the dysfunction and it's really whether that happens or not. It's probably limited a lot by the matrix Dr. Carolyn Lam: That is amazing here. Hesham, I'm going to put you on the spot. Do you have your own hypothesis about this Dr. Hesham Sadek: Based on the work that they did initially in the new England paper, we did actually a small pathology study looking at cell cycle of cardiomyocytes from the core samples and from the explanted hearts post-transplant and we saw evidence of increased cardiomyocytes cell cycle in these patients along with decreased DNA damage and some metabolic remodeling as well with mitochondria. So, you can't really tell much from tissue whether you regenerated it or not, but as you know myocytes don't divide and this is the basis for the lack of spontaneous regeneration of the myocardium. So if this in fact removes the block to cardiomyocyte cell cycle, then this might be a regenerative therapy mechanism. Dr. Carolyn Lam: Well, this is amazing. I wish we had all day to discuss this more. I mean, this is the only place you can get a discussion that goes from clinical to basic signs and back to clinical. Thank you so much, Emma and Hesham for sharing today. Thank you audience for joining us today. You've been listening to circulation on the run on behalf of Greg as well. Don't forget to tune in again next week. Speaker 1: Program is copyright the American heart association, 2020.  

The question is what is jealousy and why it comes in your mind? We can define emotions from the dictionary of words but in reality emotions have no definitive meaning. A person derives the meaning of something from his mind but the emotions are felt from the heart. The emotion of jealousy is such that for a woman, it is almost impossible for her to live without jealousy. This is the truth. A man is blind in physical attraction and a woman is blind in jealousy. Her emotions start from jealousy. She wants to keep everything to herself in jealousy. It is also that you feel jealous because you are completely devoted. It is not possible for a man to be committed the way a woman is devoted in a relationship. When a woman or a person who has completely surrendered feels that they have given their love, emotions, life, everything to the other person and if they get the feeling that some other person shares or is taking any of it then they feel it is theirs only and they own it. The seed of jealousy is ego. BREATHE / SMILE / LET GO ----------------------- SUBSCRIBE to Om Swami channel for weekly dose of positive and practical thoughts on life, meditation, spirituality, relationships & more! - https://www.youtube.com/user/omswamitv ----------------------- Want to connect & explore more. You can connect with Om Swami on https://os.me. ----------------------- If you enjoy the talks and would like to try courses by Om Swami, please visit: https://os.me/courses/ ----------------------- Need a companion in your self-discovery. You can find Om Swami's books here: https://os.me/books/ -----------------------

Kya apne kabhi socha hai ki cricket grounds ke upar chad kyu nehi lagayi jaati? Iske peeche kayi karan hai aur is podcast episode me maine yehi karan bataye hai. I hope apko ye podcast episode pasand ayega. Agar pasand aaye to share aur follow karna na bhuliyega. Thank you --- Send in a voice message: https://anchor.fm/subrata-biswas01/message

Kya apne kabhi socha hai ki Australia, England, aur New Zealand jaise desho ke cricket grounds Ke upar designs kyu bane rehte hai??? Is podcast episode me maine yehi bataya hai. Maine do reasons bataye hai - historical aur modern, jiske karan se aesa designs ground ke upar banaye jaate hai. I hope ye podcast episode apko pasand ayega. Agar pasand aaya to share aur follow karna na bhuliyega. Thank you --- Send in a voice message: https://anchor.fm/subrata-biswas01/message

Uparłam się żeby zrobić z nim wywiad. Jakoś tak czułam w sercu, że mam ten wywiad zrobić. Jak poczułam tak zrobiłam. Czekałam parę miesięcy aż w końcu wczoraj się udało. To mądra i wartościowa rozmowa o postawieniu wszystkiego na jedną kartę, o tym że praktycznie wszystko rodzi się w naszym życiu z naszej pasji, która kształtuje nas jako ludzi. Michał jest obserwatorem świata, reportarzystą. Swoim aparatem opisuje ludzkie historie. Kiedy wczoraj po raz pierwszy usłyszałam jego głos pomyślałam sobie, że to jest dobry człowiek. I taki jest, facet o wrażliwej duszy, który ma w sobie bardzo duże pokłady kreacji i dobre serce. Tym razem zapraszam nie tylko do wysłuchania, ale także do obejrzenia, bo jest w tym wywiadzie sporo Michała zdjęć. Lubie takie rozmowy, szczere, autentyczne, w których czujesz, że człowiek robi w życiu to, co kocha. A mi jakoś tak blisko jest do takich ludzi.

Unke Upar Hi Gurukrupa Utarti Hai : Manoj Bhai Gurubhaktiyoga

Unke Upar Hi Gurukrupa Utarti Hai : Manoj Bhai Gurubhaktiyoga

Bhaj Govindam  Verse 2  Mudha jahihi dhanagama trshna Kuru sadhbuddhim manasivi trshnam I Yallabhase nijakarmopattam Vittam tena vinodaya chittam I The second verse said to me - Sruti says

When friends get together, fun times are sure to follow!  Check out Ranvir, Ankur and Sidd jamming to Upar Neeche

In this episode of Fever FM production Soul Yatra, learn from Life Coach Sharat ki God hum se kabhi naraz nahi hote. Tune into this HT Smartcast every morning.

भोजपुरी फिल्मो के एक्टर विशाल सिंह पर हाल ही में एक केस दर्ज किया गया था जिसके बारे में विशाल सिंह ने पहली बार अपनी सफाई दी.

Check out Gur Ke Charan upar Mere Mathe by Bhai Niranjan Singh (Jawaddi Taksal)

#rjraunac #redfm #bajaateraho #bauaa #sukumar #podcast

Tum Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Tum Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

Tum Upar Utho : Pujya Sant Shri Asharamji Bapu Satsang

How to determine if audible content impacts comprehension. Based on the work by Dr. Denise DeCoste and Linda Bastiani Wilson, The part is a systematic assessment process to determine if audible text impacts comprehension and factoring in is there a difference between human voices and digitized voices. See DonJohntson.com uPar for more information.

Chhogala Tara Chhogla Upar by Shree Swaminarayan Mandir Kalupur

Denise HILFIKER-KLEINER, Dean of Research, Molecular Cardiology, Department of Cardiology and Angiology, MHH, Hannover, GERMANY speaks on "Pathophysiology of Peripartum Cardiomyopathy links Prolactin to the PAI-1/uPAR system: Modulation of NF-kB signaling and miR146a as therapeutic options". This movie has been recorded at ICGEB Trieste.

New episode! We talk/rant about the upcoming award season, review two more songs from Bajirao and Dilwale, and disagree about Tamasha (whoops)! Songs played in the podcast ~ Tu Mere Paas (Wazir) ~Janam Janam (Dilwale) ~ Malhari (Bajirao Mastani) ~ Main Rahoon Ya Na Rahoon

Episode 3 of Season 3 brings you spicy stories on affairs and splits in Ajay, Kangana and Neil's life, frown upon another Bachchan inspired movie and fight over Tere Mere Kahani. Songs played in the podcast ~Jugni~ Cocktail, Hunter ~ Gangs of Wasseypur , Tu hi hai Bandhu ~ Cocktail and Hum se Pyar Karle Tu ~ Tere Mere Kahani. Get back to us with opinions, complaints, requests and/or love on twitter @ masala_chaat or chaatmasalaradio@gmail.com

The study is subdivided into two different parts: the first part deals with the development of a method to gain uterus milk in vivo during the preimplantation periode in cattle for the investigation of regulatory factors. The second part investigates different proteases in bovine follicles 20 hours after GnRH (Gonadotropin releasing hormone) injection (shortly bevor ovulation) for comparable as well as in the corpus luteum (CL) during oestrous cycle and induced luteolysis. In addition apoptotic as well as anti-apoptotic factors were evaluated in the CL during oestrous cycle and induced luteolysis. For the development of a method for gaining uterus milk in vivo during the first 24 days of gravidity in cattle, nine heifers were cycle synchronised using the Ovsynch method and artificially inseminated. Before flushing an epiduralanaesthesia was given and both uterus horns were flushed with 13ml 0.9% NaCl using a balloon embryo transfer catheter at day 5, 7, 12, 17 and 24 of gravidity. The catheter was placed 1cm cranial to the bifurcatio uteri in both horns. It was possible to retrive between 3ml and 13ml of the used flushing fluid. The uterus milk from the ipsilateral horn was inspected for an embryo and an EDTA-stabilisator was given to the uterus milk of both horns. An infection of the uterus occured in three heifers after the second and in five heifers after the third flushing. In one heifer no infection was found. Between day 17 and day 24 all heifers showed clear signs of oestrus. It was possible to detect progesterone, oestradiol-17-beta, PGF2alpha and VEGF via enzyme immunoassay (EIA) and radio immunoassay (RIA), respectively. Because of the occurred infection no statistic analysis was made. But it could be seen that the level of progesterone ranged between

In dieser Arbeit wurde zum ersten Mal der Einfluss des potentiellen Tumorsuppressors Pdcd4 auf das invasionsassoziierte Urokinase-Rezeptorgen(uPAR), sowie auf den Invasionsvorgang selbst, untersucht. In verschiedenen gastrointestinalen Karzinomzelllinien wurde eine gegenläufige Expression von uPAR und Pdcd4-mRNA und -Protein nachgewiesen. In Reportergen-Assays unter Verwendung von Wildtyp- und mutiertem uPAR-Promotor zeigte sich nach gleichzeitiger Transfektion von Pdcd4 eine dosisabhängige Suppression der uPARPromotoraktivität. Ferner wurden verschiedene cis-Elemente innerhalb des Promotors als potentielle Mediatoren dieser Regulation identifiziert. Bei diesen handelt es sich potentiell um die Region -402/-350bp mit mutmaßlichen Bindestellen für Sp-1, GATA-1, NF-1 und einem PEA3/ets Element an Position -245 bp. Zusätzlich konnte durch eine Mutation der kombinierten Bindungstelle für Sp-1 und Sp-3 an Position -152/-135bp, die über Pdcd4 ermittelte Suppression der Promotoraktivität aufgehoben werden. In Gelshiftanalysen zeigte sich neben einer verminderten Bindung von Transkriptionsfaktoren der GATA- und Sp-Familie innerhalb der Region -402/-350bp insbesondere eine Erhöhung der Bindung von Sp-3 an Promotorregion - 152/-135bp. Dies impliziert neben den oben genannten Mediatoren, dass Pdcd4 durch Induktion der Bindung von Sp-3 an dieses Element den uPAR-Promotor supprimiert. Darüber hinaus konnte durch die Expression von Pdcd4 die Invasionsfähigkeit der Kolonkarzinomzellinie HCT-116 in vivo reduziert werden. Diese Ergebnisse zeigen, dass Pdcd4 die Promotoraktivität von uPAR über verschiedene cis-aktive Elemente des Promotors supprimiert und belegen erstmals die Regulation eines invasionsassoziierten Gens durch den potentiellen Tumorsuppressor Pdcd4. Ferner wird erstmals Sp-3 als Mediator der Pdcd4 vermittelten Genexpression vorgeschlagen. Daneben postulieren die Invasionsdaten auch eine Funktion von Pdcd4 als potentiellen Suppressor von Teilschritten der Metastasierungskaskade. Zusätzlich konnte in dieser Arbeit ein neues quantitatives CAM-Modell etabliert werden, das die Invasion und Intravasation von Tumorzellen in vivo spezifisch im Hühnerei-Modell untersucht. Das Protokoll unterscheidet sich von den bisher publizierten Arbeiten durch die Verwendung einer spezifischen TaqMan®-Probe in Zusammenfassung 116 Kombination mit Primern, die spezifisch humane Alu-Sequenzen der YB8-Unterfamilie nachweisen. Durch diese Modifikationen wurde eine höhere Sensitivität der quantitativen Alu-PCR erreicht. Zusätzlich eröffnet die Spezifität der hier entwickelten Primer über den CAM-Assay hinaus die Möglichkeit, humane Zellen und Mikrometastasen auch in murinen in vivo Modellen wie SCID- oder Nacktmäusen nachzuweisen.